ARNA : Analysis & Opinions

  1. Arena Pharmaceuticals Extends Its Winning Streak (ARNA, CELG)

    March 28, 2016
    While Arena is riding a wave of optimism, the company must still execute on its own to get its shares out of penny stock ...
  2. Why Arena Pharmaceuticals Surged 10% Last Week (ARNA)

    March 21, 2016
    Arena Pharmaceuticals, which operates at a negative cash flow of $98 million, saw its stock rise in sympathy to favorable ...
  3. How Speculation Drives Investment in Arena Pharmaceuticals (ARNA)

    March 14, 2016
    Find out the reasons why biotech firm Arena Pharmaceuticals is a speculative play and how speculators are driving investment ...
  4. Analyzing Arena Pharma's Return on Equity (ARNA, IMGN)

    March 8, 2016
    Explore Arena Pharmaceutical's return on equity (ROE) and find out what is driving its significant negative returns. Find ...
  5. The Future of the Marijuana Industry in America

    November 10, 2015
    Polls show that most Americans favor legalization, and studies on the use of medical marijuana have been promising. Should ...
  6. Marijuana Penny Stocks: Where Risk Meets Sin

    September 7, 2015
    Marijuana producers and users, working in a market that's still illegal in many states, are a risky but promising bet for ...
  7. 5 Key Takeaways Following Arena's Q1 Results (ARNA, ESALY)

    May 13, 2015
    Arena Pharmaceuticals (NASDAQ: ARNA) this week reported first-quarter financial results that have investors wondering whether ...
  8. 3 Things Arena's Management Wants You to Know (ARNA, ESALY)

    May 7, 2015
    The battle for market share in the highly competitive obesity market is heating up, and there's likely to be significant ...
  9. 3 Ways Arena Can Boost Shareholder Value (ARNA, IMGN)

    April 2, 2015
    Following the approval of weight control management drug Belviq by the Food and Drug Administration in 2012, Arena Pharmaceuticals ...
  10. Is Arena Pharmaceuticals In Trouble? (ARNA)

    March 5, 2015
    Arena Pharmaceuticals' approval of its weight-loss drug Belviq in 2012 has brought anticipations so high that its share price ...
  11. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  12. Weight Watchers Still Can't Get It Right

    February 15, 2013
    Weight Watchers offers more excuses and poor performance.
  13. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  14. Weight Watchers May Be The Best House On An Awful Street

    November 6, 2012
    Weight Watchers continues to struggle to exploit its huge market opportunity.
  15. Arena Pharmaceuticals – One Huge Step Forward, But Many More ...

    June 28, 2012
    ARNA shareholders got some major validation on June 27, 2012, when the company announced that the FDA had formally approved ...
  16. Control May Be Herbalife's Real Long-Term Problem

    June 4, 2012
    Herbalife's model may not be as precarious as feared, but there are some weaknesses and the stock may only see 10% compound ...
  17. Wall Street Isn't Buying The Medifast Story

    March 5, 2012
    Medifast gets a lot of doubt on the Street.
  18. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  19. Arena's New Data Doesn't Change Obesity Pill Outlook

    May 30, 2011
    Arena's new data isn't new and doesn't address the company's biggest issues.
  20. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  21. FDA Locked And Loaded For MELA Sciences

    November 16, 2010
    A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
  22. FDA To Obesity Drugs: Drop Dead

    September 20, 2010
    An FDA panel knocks down yet another would-be obesity drug.
  23. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
Trading Center